| HOME >> BIOLOGY >> TECHNOLOGY |
Add estimated non-cash stock compensation $27.0 million
Non-GAAP estimated net income for 2008 $47 - $67 million
Management believes that this non-GAAP information is useful to
investors, taken in conjunction with BioMarin's GAAP net income guidance
for 2008 because Management uses such information internally for its
operating, budgeting and financial planning purposes, and to enhance
investors' overall understanding of the company's prospects for the future.
Anticipated Upcoming Milestones
-- 1Q08/early 2Q08: Initiation of PEG-PAL Phase I patient study with
plans to roll into a Phase 2 study in 3Q08
-- 4Q08: Results from Phase 2 Sickle Cell Disease trial
-- 4Q08: Results from Phase 2 PAD trial
Upcoming Investor Conferences and Events
-- March 17-19: Citi Small/Mid Cap Conference -- Las Vegas
-- March 17-20: Cowen Healthcare Conference -- Boston
-- March 18-20: Lehman Brothers Global Healthcare Conference -- Miami
-- June 5: BioMarin R&D Day -- New York City
BioMarin will host a conference call and webcast to discuss fourth
quarter and full year 2007 financial results today, Tuesday, February 26,
at 5:00 p.m. ET (22:00 CET). This event can be accessed on the investor
section of the BioMarin website at http://www.BMRN.com.
Date: February 26, 2008
Time: 5:00 p.m. ET (22:00 CET)
U.S. / Canada Dial-in Number: 866.713.8564
International Dial-in Number: 617.597.5312
Participant Code: 79434433
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 87203261
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for
serious diseases and medical conditions. The company's product portfolio
comprises three approved products and multiple clinical and pre-cl
'/>"/>
| SOURCE BioMarin Pharmaceutical Inc. Copyright©2008 PR Newswire. All rights reserved |